24.9 C
New York
Thursday, June 4, 2026

Tag: infection

newssourceFORcompanyinformationcontent1marketreleases

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10...

Bask and Lather Co. Named to the 2025 Inc. 5000 List of America’s Fastest-Growing Private Companies

With Three-Year Revenue Growth of 500% Percent, This Marks Bask & Lather's First Time on the List NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Inc.,...

Fosun Pharma’s Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License...

Boehringer Ingelheim Celebrates Next Generation of Biomedical Researchers at 2025 Veterinary Scholars Symposium

Student researchers from Mississippi State University and The Ohio State University received Boehringer Ingelheim research awards DULUTH, Ga., Aug. 11, 2025 /PRNewswire/ -- Veterinary research took...

REPEAT — Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion...

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $18 billion and $22 billion. This forecast reflects the company’s unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.

Public health notice: Outbreak of Salmonella infections linked to various brands of pistachios and pistachio-containing products

August 8, 2025: Update OTTAWA, ON, Aug. 8, 2025 /CNW/ - This outbreak investigation is ongoing. The public health notice will be updated as the investigation...

DermaRite Industries Issues Voluntary Nationwide Recall of DermaKleen, Dermasarra, Kleenfoam, and Perigiene Products Due to Burkholderia cepacia Contamination

NORTH BERGEN, N.J., Aug. 8, 2025 /PRNewswire/ -- DermaRite Industries, LLC is voluntarily recalling individual lots of products in the table below due to...

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 99,000 shares of Class A common stock and restricted stock units (RSUs) underlying 48,200 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

WCC Biomedical@NACDS Total Store Expo: Advancing Microneedle Drug Delivery With WINMAP™ Platform

TAIPEI, Aug. 8, 2025 /PRNewswire/ -- WCC Biomedical, a leader in novel drug delivery systems, will attend the upcoming NACDS Total Store Expo (TSE), where...

Peracetic Acid Market worth $1.67 billion in 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 7, 2025 /PRNewswire/ -- The report "Peracetic Acid Market by Grade (<5% Grade, 5–15% Grade, >15% Grade), Application (Disinfectant, Sterilant,...

Peracetic Acid Market worth $1.67 billion in 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 7, 2025 /PRNewswire/ -- The report "Peracetic Acid Market by Grade (<5% Grade, 5–15% Grade, >15% Grade), Application (Disinfectant, Sterilant,...

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ® in individuals 60 years of age and older and has approved updates to the Prescribing Information (PI) for IXCHIQ®. IXCHIQ® remains indicated in the United States for the prevention of disease caused by the Chikungunya Virus (CHIKV) in individuals 18 years of age and older who are at high risk of exposure to CHIKV.

Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®

AHMEDABAD, India, Aug. 7, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as...

Forte Medical National Survey Announcement

UK MedTech company launches patient experience survey around overlooked & unreliable Urinary Tract Infection and prenatal screening diagnostics.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInfection

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers